Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05986565 · ClinicalTrials.gov registry record · NA
Study of the Families Moving Forward Website Behavioral Intervention for Teachers of Students With Fetal Alcohol Spectrum Disorder
A NA study of Fetal Alcohol Spectrum Disorders, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT05986565: Completed NA study of Fetal Alcohol Spectrum Disorders, sponsored by University of Rochester.
NCT05986565 is a NA study of Fetal Alcohol Spectrum Disorders that has completed, run by University of Rochester. The registered enrollment target is 37 participants, below the 102-participant average among 10 other Fetal Alcohol Spectrum Disorders trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05986565, a NA study of Fetal Alcohol Spectrum Disorders, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if the FMF Connect Teacher Companion website is acceptable and usable by teachers. The FMF Connect Teacher Companion website is a website for teachers adapted from the Families Moving Forward (FMF) Program. The FMF Program is an evidence-based intervention for caregivers of children with FASD. The study will determine if the a web page intervention is feasible and acceptable by looking at enrollment and retention of study subjects and acceptability of assessments.
Primary Outcome
Teacher FASD knowledge will be measured using the "Fetal Alcohol Spectrum Disorder (FASD) Knowledge" survey. The survey scores range from 0-33 with higher scores indicating more knowledge about FASD.
Conditions Studied
Interventions
- BEHAVIORAL Families Moving Forward (FMF) Teacher adapted training
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2023-08-24 |
| Est. Completion | 2024-01-29 |
| Phase | NA |
What the finished NCT05986565 record still lists
NCT05986565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 102-participant average among 10 other Fetal Alcohol Spectrum Disorders trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Fetal Alcohol Spectrum Disorders appearing as the primary indexed condition, and to 1 intervention - of which Families Moving Forward (FMF) Teacher adapted training is the first listed.
NCT05986565 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05986565 about?
NCT05986565 is a clinical study titled "Study of the Families Moving Forward Website Behavioral Intervention for Teachers of Students With Fetal Alcohol Spectrum Disorder". The purpose of this study is to find out if the FMF Connect Teacher Companion website is acceptable and usable by teachers. The FMF Connect Teacher Companion website is a website for teachers adapted from the Families Moving Forward (FMF) Program. The FMF Program is an evidence-based intervention fo...
What is the current status of trial NCT05986565?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2023-08-24. Estimated completion is 2024-01-29.
What conditions does trial NCT05986565 study?
This clinical trial studies the following conditions: Fetal Alcohol Spectrum Disorders.
What interventions are being tested in trial NCT05986565?
The interventions under investigation include: Families Moving Forward (FMF) Teacher adapted training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05986565?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05986565 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fetal Alcohol Spectrum Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05986565's enrollment target sits among peer trials
37 9th of 10 higher than 2 of 10 other Fetal Alcohol Spectrum Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fetal Alcohol Spectrum Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Oklahoma Parent-Child Assistance Program
RECRUITING · NA
-
CIFASD 5 tDCS and Cognitive Training
RECRUITING · NA
-
Families Moving Forward (FMF) Connect Pro for Mental Health Providers
RECRUITING · NA
-
The Synchrony Study: Examining Music Training for Children With FASD
RECRUITING · NA
-
Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure
RECRUITING · NA
-
My Health Coach App RCT
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI